Study guide

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations

Key Takeaways Explain This Topic AI

Migraine is about three times more common in women; migraine with aura makes estrogen-containing contraception US MEC Category 4 because of ischemic stroke risk.

Triptans treat moderate to severe migraine but are contraindicated in coronary or cerebrovascular disease and uncontrolled hypertension; gepants and lasmiditan are alternatives.

Preventive therapy is considered with 4 or more headache days per month; topiramate and valproate are teratogens, and topiramate above 200 mg/day can lower contraceptive hormone levels.

Medication-overuse headache develops with simple analgesics on 15 or more days per month or triptans on 10 or more days per month.

A new or changed headache in pregnancy or postpartum, a thunderclap onset, neurologic signs, papilledema, or new headache after 50 needs urgent evaluation (SNOOP4 red flags).

Last updated: October 2026

Primary Headache Types

Feature Migraine Without Aura Migraine With Aura Tension-Type Cluster

Typical patient Women about 3:1; peaks ages 25–55 Same Most common headache overall More common in men, but women are affected

Duration 4–72 hours Aura of 5–60 minutes, then headache 30 minutes to 7 days 15–180 minutes, often daily in clusters

Character Unilateral, pulsating, moderate to severe, worse with activity Same, preceded by fully reversible visual, sensory, or speech symptoms Bilateral, pressing or band-like, mild to moderate Severe unilateral orbital pain

Associated Nausea or vomiting, or photophobia and phonophobia Same No nausea; at most one of photophobia or phonophobia Tearing, rhinorrhea, ptosis, and restlessness on the same side

Migraine diagnosis (ICHD-3) requires at least 5 attacks meeting these features. Aura most often shows as a zigzag scintillating scotoma spreading over minutes.

Why Aura Matters in Women's Health

Migraine with aura roughly doubles ischemic stroke risk, and estrogen adds to it. Combined hormonal contraception is US MEC Category 4 for migraine with aura at any age (Category 2 for migraine without aura under 35, and 3 at 35 or older). Progestin-only methods and IUDs are Category 1–2. Always ask about aura before prescribing estrogen.

Acute Migraine Treatment

Mild to moderate attacks: NSAIDs (ibuprofen, naproxen), aspirin, or acetaminophen-aspirin-caffeine, taken early.

Moderate to severe attacks: Triptans (sumatriptan, rizatriptan, others), alone or combined with an NSAID. Triptans are contraindicated in coronary artery disease, stroke or TIA, peripheral vascular disease, uncontrolled hypertension, and hemiplegic or brainstem aura ; typical migraine with aura is not a contraindication.

When triptans are contraindicated or fail: Gepants ( ubrogepant, rimegepant ), which do not constrict vessels, or lasmiditan (causes driving impairment for 8 hours).

Nausea: Metoclopramide or prochlorperazine, which also relieve headache.

Avoid opioids and butalbital compounds, which worsen outcomes and lead to overuse.

Medication-Overuse Headache

Using simple analgesics on 15 or more days per month or triptans, combination analgesics, or opioids on 10 or more days per month for more than 3 months can cause daily headache. Treat by withdrawing the overused drug and starting prevention.

Preventive Therapy

Consider prevention with 4 or more headache days per month , disabling attacks, or failure of acute treatment.

Drug Notes for Women

Propranolol or metoprolol First-line; propranolol is acceptable in pregnancy when needed (monitor fetal growth)

  • Amitriptyline Helps coexisting insomnia or tension-type headache
  • Venlafaxine, candesartan Alternatives (avoid candesartan in pregnancy)

Topiramate Effective but teratogenic (oral clefts) ; doses above 200 mg/day lower contraceptive hormone levels ; cognitive side effects

Valproate Avoid in people who could become pregnant (neural tube defects, lower child IQ)

CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and atogepant or rimegepant Effective and well tolerated; limited pregnancy data, so stop several months before conception

  • OnabotulinumtoxinA For chronic migraine (15 or more headache days per month)
  • Menstrual Migraine

Attacks occur from 2 days before through 3 days after the start of menses, triggered by estrogen withdrawal . Options include frovatriptan or naratriptan "mini-prophylaxis" during that window, scheduled NSAIDs, or extended or continuous combined hormonal contraception to remove the hormone-free interval (only if there is no aura ).

Other Headache Disorders

Tension-type headache: Treat with NSAIDs or acetaminophen, stress management, and physical therapy; use amitriptyline for frequent episodes.

Cluster headache: Abort attacks with 100% oxygen at high flow or subcutaneous sumatriptan; prevent with verapamil (ECG monitoring).

Idiopathic intracranial hypertension: Typically young women with obesity ; daily headache, pulsatile tinnitus, transient visual obscurations, and papilledema , with a risk of permanent vision loss. Confirm with imaging and lumbar puncture (high opening pressure); treat with weight loss and acetazolamide. Tetracyclines, excess vitamin A, and isotretinoin are triggers.

Red Flags: SNOOP4

Letter Red Flag Possible Cause

S Systemic symptoms (fever, weight loss) or secondary risk (cancer, HIV, immunosuppression) Infection, metastasis

N Neurologic signs or confusion Stroke, mass, infection

O Onset sudden ("thunderclap") , maximal within a minute Subarachnoid hemorrhage , reversible cerebral vasoconstriction

O Older age at onset (over 50) Giant cell arteritis (check ESR and CRP), mass

P Pattern change, progressive headache, positional headache, precipitated by Valsalva, papilledema , or pregnancy and postpartum Mass, intracranial pressure changes, cerebral venous thrombosis, preeclampsia

Headache in Pregnancy and Lactation

Migraine, especially without aura, often improves in the second and third trimesters and may recur postpartum.

Acute treatment: Acetaminophen first, with metoclopramide; sumatriptan is reasonable when needed (pregnancy registry data are reassuring). Avoid NSAIDs after about 20 weeks, and avoid ergotamine and dihydroergotamine , which are contraindicated.

Prevention: Propranolol or amitriptyline if needed; avoid topiramate and valproate.

A new or different headache after 20 weeks or postpartum must be evaluated for preeclampsia , as well as cerebral venous thrombosis, reversible cerebral vasoconstriction syndrome, posterior reversible encephalopathy syndrome, and post-dural puncture headache (see the puerperal complications section).

Lactation: Ibuprofen, acetaminophen, and sumatriptan are compatible with breastfeeding.